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Abstract
Background:  'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) is a form of psychotherapy specifically
developed for patients with chronic depression. In a study in the U.S., remarkable favorable effects of CBASP have been
demonstrated. However, no other studies have as yet replicated these findings and CBASP has not been tested outside the
United States. This protocol describes a randomized controlled trial on the effectiveness of CBASP in the Netherlands.
Methods/Design: The purpose of the present paper is to report the study protocol of a multisite randomized controlled trial
testing the effectiveness of 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) for chronic depression in the
Netherlands. In this study, CBASP in combination with medication, will be tested versus usual secondary care in combination
with medication. The aim is to recruit 160 patients from three mental health care organizations. Depressive symptoms will be
assessed at baseline, after 8 weeks, 16 weeks, 32 weeks and 52 weeks, using the 28-item Inventory for Depressive
Symptomatology (IDS). Effect modification by co morbid anxiety, alcohol consumption, general and social functioning and
working alliance will be tested. GEE analyses of covariance, controlling for baseline value and center will be used to estimate the
overall treatment effectiveness (difference in IDS score) at post-treatment and follow up. The primary analysis will be by
'intention to treat' using double sided tests. An economic analysis will compare the two groups in terms of mean costs and cost-
effectiveness from a societal perspective.
Discussion: The study will provide an answer to the question whether the favorable effects of CBASP can be replicated outside
the US.
Trial Registration: The Dutch Cochrane Center, NTR1090.
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Background
According to the World Health Organization, Major
Depressive Disorder (MDD) is the second largest health-
care problem worldwide in terms of limitations caused by
illness [1]. MDD causes high rates of subjective suffering,
absenteeism and utilization of medical services [2]. Both
in the Netherlands and elsewhere it was found that 20%
of depressions still persist after two years [3,4]. Chronic
MDD causes a greater illness burden, more suicide
attempts and more hospital admissions compared to
acute MDD [5,6]. In outpatient mental health popula-
tions, chronic MDD affects an estimated 25–35% of
depressive patients [7,8]. Unfortunately, the treatment
results for this group of depressed patients are often disap-
pointing and the existing treatment protocols are insuffi-
ciently tailored to chronic MDD [9]. For this reason, an
effective psychotherapeutic treatment will constitute a
welcome addition to the range of treatments currently
available for chronically depressed patients.
Although there is a reasonably large body of literature
evaluating cognitive as well as interpersonal therapy for
nonchronic or mixed depressed samples, few studies have
specifically investigated the group of chronically
depressed patients [10]. A study that did target this group
of patients examined the effectiveness of 'Cognitive
Behavioral Analysis System of Psychotherapy' (CBASP), a
form of psychotherapy that was specifically developed for
chronic depression. CBASP's core procedure is called "sit-
uational analysis", a highly structured technique that
teaches chronically depressed patients to fix their prob-
lematic interpersonal encounters. It is designed to teach
patients that their behavior has consequences (called per-
ceived functionality) by focusing on situational conse-
quences to change their thoughts and behavior. CBASP
conceptualizes that the interpersonal difficulties these
patients encounter outside the therapy are also likely to
emerge in the therapeutic relationship [11]. These difficul-
ties are anticipated through "transference hypotheses" for-
mulated early in treatment, which helps the therapist to
recognize and resolve therapeutic impasses [9,12].
In a multisite trial involving 681 patients suffering from
chronic depression, Keller and colleagues [13] compared
the efficacy of an antidepressant (nefazodone), CBASP
alone and their combination. After 12 weeks of treatment
CBASP alone was equally effective as nefazodone alone
[response rate of 48%]. The combination of nefazodone
and CBASP was the most effective treatment [response
rate of 73%]. After four months continuation treatment
the authors found no difference between nefazodone and
CBASP and found an ongoing advantage for combined
treatment. Furthermore, over 85% of responders after 12
weeks of treatment maintained that response in continu-
ation [14]. After 52 weeks of treatment, it was also found
that CBASP was effective as a maintenance treatment for
chronic depression [15].
In addition, it was found that CBASP was a good alterna-
tive for patients who were not motivated for, or refractory
to medical treatment. For the non-responders in the study
it was found that the switch from nefazodone to CBASP
and vice versa resulted in clinically and statistically signif-
icant improvements [16,17].
As a result of these findings, CBASP is mentioned as an
evidence based treatment option for chronic depression
in the Dutch treatment guidelines [18]. However, the
results of the American study have not yet been replicated.
In addition, the dissemination of CBASP outside the US is
limited. In order to test whether these findings can be rep-
licated in a Dutch population we designed a randomized
controlled trial on the effectiveness of CBASP. Our
research questions are:
1. Is CBASP more effective and cost-effective than usual
secondary care?
2. Which patient related factors predict a beneficial
response?
Methods/Design
Study design
This study is a multi-center randomized controlled trial in
which the effects of CBASP will be evaluated. CBASP, in
combination with antidepressant treatment, will be tested
versus usual secondary care in combination with antide-
pressant treatment over 52 weeks follow-up. The aim is to
establish the clinical and cost effectiveness of CBASP plus
antidepressant treatment in secondary care.
Recruitment/Settings and locations
Patients will be recruited within the mood disorder
departments of three organizations for mental health care
in Amsterdam and The Hague. All newly registered
patients will first be seen by a psychologist or psychiatrist
for an intake and screening interview, which is part of a
standard procedure. After the intake procedure patients'
diagnosis and indication will be discussed in a staff meet-
ing. At each site, the research-coordinator of the study will
attend the staff meetings to select the patients diagnosed
with chronic depression. These patients will be
approached for participation in the study. The coordina-
tor will be screening the patients on the inclusion-exclu-
sion criteria of this study and inform them about the
study. If patients are willing and eligible to participate,
written informed consent will be elicited. The inclusion
period will cover one year.BMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
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Participants
Inclusion criteria
Patients (aged 18–65) are eligible to participate if their
main diagnosis is a chronic form of depression according
the DSM-IV criteria: a) a chronic major depressive disor-
der (i.e. existing for longer than 2 years) or b) a major
depressive disorder superimposed on a dysthymic disor-
der or c) a recurrent major depressive disorder which, in
the past 2 years, never fully remitted between the epi-
sodes. The Mini International Neuropsychiatric Interview
plus (M.I.N.I. plus), a structured diagnostic interview
developed in 1990 by psychiatrists and clinicians in the
United States and Europe for DSM-IV and ICD-10 psychi-
atric disorders, will be used to assess chronic depression
[19,20]. In addition, the level of symptom severity should
be moderate to severe, expressed as a score of 22 or more
on the 28-item Inventory for Depressive Symptomatology
(IDS) [21,22].
Exclusion criteria
Patients are excluded from the study if: a) they suffer from
one (or more) of the following disorders: a psychotic dis-
order, bipolar disorder, organic brain syndrome, sub-
stance dependence, or a severe borderline -, schizotypical
-, or antisocial personality disorder or b) they have high
risk of suicide c) they do not have sufficient command of
the Dutch language necessary to participate in the study.
Randomization
After signing the informed consent form, patients will
enroll in the study and start with the baseline interview.
After completing the baseline interview, patients will be
assigned at random to either the intervention group or the
control group. The intervention group will receive CBASP,
while the control group will receive treatment as usual.
Randomization will be performed by an external
researcher using a computerized random number genera-
tor. Randomization is stratified per location.
Assessments
Data are collected at five points in time: at baseline (T0),
after 8 weeks of treatment (T1), after 16 weeks of treat-
ment (T2), after 32 weeks of treatment (T3), and at the
endpoint, after 52 weeks of treatment (T4). The Quick
Inventory of Depressive Symptomatology self-report [23]
will be assessed monthly. Table 1 summarizes the meas-
ures that are used at each point. The assessments will be
performed by an experienced research nursing staff. At
baseline and endpoint there will be a face-to-face inter-
view besides the written questionnaires; the three assess-
ments in between consist of written questionnaires only.
The research nursing staff from the three participating
organizations will participate in a two-day training course
to make sure the measures are conducted the same way at
the different locations.
Outcome measures
Primary outcome measure
The primary outcome measure is the reduction of depres-
sive symptoms measured with the 28-item version of
Inventory of Depressive Symptoms (IDS). The IDS is a
measure of symptom severity in depression that has been
used to assess acute and longer-term outcomes and has
highly acceptable psychometric properties (Cronbach's
alpha = .92) [21,22]. The IDS self-report version will be
administered at baseline, after 8, 16 and 32 weeks and at
the end of the study, at 52 weeks follow-up. Patients with
a 50% symptom reduction on the IDS, are responders
[13]. Remission is defined as an IDS score of 13 or less.
Secondary measures of outcome/predictors of response
To assess chronic depression and co morbid disorders at
baseline and at the end of the study patients will receive a
diagnostic interview using the M.I.N.I. plus [19,20].
Information on demographic factors (age, gender, marital
status, education, professional occupation) will be col-
lected in the baseline interview and at the end of the
study.
Putative modifiers of effect are well known risk-factors for
chronic depression [24], these are: level of functioning,
which will be measured using the WHODAS [25], social
contacts and social participation using the Loneliness &
Affiliation Scale [26] and the Social Participation Scale
[27], locus of control using the Mastery Scale [28] and
psychological well being using the Psychological Well
Being Scales (PWB) [29]. Physical health and diseases will
be measured by a validated Dutch questionnaire [30],
psychological mindedness using the Lack of Psychological
Mindedness (LPM) [31] and parental relationship using
the Remembered Parenting Scale (RRP) [31]. The Mood
Disorder Questionnaire (MDQ) [32] will be used to meas-
ure bipolar symptoms, number of depressive episodes in
the past five years using the Life Chart [33], anxiety using
the Beck Anxiety Inventory (BAI) [34], alcohol depend-
ence using the Alcohol Use Disorders Identification Test
(AUDIT) [35], recent trauma using the Brugha question-
naire [36] and childhood trauma using the Nemesis ques-
tionnaire [37]. Personality will be measured using the
NEO-Five Factor Inventory (NEO-FFI) [38] and working
alliance using the Working Alliance questionnaire [39].
All measures of outcomes are widely used internationally,
are reliable and valid, also for usage in the Netherlands.
Interventions
For this project 'the founder' of CBASP, J.P. McCullough
Jr., came to Amsterdam to train the 25 therapists partici-
pating in this study. A four day workshop was given dur-
ing which the basic techniques of CBASP were taught. FiveBMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
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therapists, subsequently, followed an intensive training
by McCullough in the US to become CBASP Supervisors.
They will supervise the participating therapists during the
study. The therapy will be carried out as specified in the
CBASP protocol [40-42]. The treatment protocol for the
therapists and manual for the patients have been trans-
lated into Dutch. All therapists have to treat two patients
under supervision before being allowed to treat patients
in the study. All CBASP sessions will be audio taped, and
the supervisors will review the audiotapes to assess the
psychotherapists' adherence to the treatment procedures
(McCullough, Jr. J.P. (1995). Adherence Scale. Unpub-
lished Scale. Richmond, VN: Virginia Commonwealth
University). Supervision will be given on a weekly basis.
CBASP
The central idea of CBASP is that chronically depressed
patients fail to recognize the connection between their
behavior and interpersonal/environmental consequences.
In other words, they do not grasp their own contribution
to the life difficulties they encounter. The major goals of
CBASP are to help patients 1) to understand the conse-
quences of their behavior, 2) to change their patterns of
coping, and 3) to improve their interpersonal skills [9].
Table 1: Summary of measures
Measure Baseline 8 week follow-up 16 week follow-up 32 week follow-up 52 week follow-up
Interview:
Mini plus measures diagnostics x x
Demographics x x
CBS questionnaire measures physical health x x
LIFE-CHART measures duration of 
depression
x
NEMESIS questionnaire of childhood 
trauma
x
Brugha questionnaire of recent life events x x
Self report measurements:
Inventory of Depressive Symptoms (IDS) x x x x x
Quick Inventory of Depressive Symptoms 
(QIDS)
Monthly assessment
Beck's Anxiety Inventory (BAI) x x x x x
AUDIT measure of alcohol consumption x x x x x
Working alliance questionnaire-patient 
version
xx x
Mastery scale measures locus of control x x x x x
Social activity/participation x x x x x
WHODAS x x x x x
Loneliness & Affiliation Scale x x
NEO-Five Factor Inventory x x
Mood Disorder Questionnaire x x
Psychological Well Being (PWB) x x
Lack of Psychological Mindedness (LPM) x x
Remembered Parenting Scale (RRP) x
Questionnaires for economic 
evaluation:
Registration of usage medication x x
TIC-P measures illness and work x x
Perceived need for care x x
TIC-P work + health care utalization self 
report
xx
Questionnaires filled in by therapists: Baseline 8 week follow-up 16 week follow-up 32 week follow-up 52 week follow-up
Clinical Global Impression-Improvement 
(CGI)
xx x x
Working alliance questionnaire, therapist 
version
xx xBMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
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CBASP is highly structured, focuses on teaching social
problem skills, and makes use of regular homework
assignments. The main focus is on interpersonal problems
with significant others, but also in the therapist-patient
relationship. The relationship with the therapist is used as
a tool to help patients to become more aware of their
impact on others and to distinguish between adaptive and
maladaptive relationships [9].
CBASP consists of a total of 26–30 sessions in a period of
a year. CBASP starts with bi-weekly sessions in the first 4
weeks followed, in principle, by one session per week
from week 5–16. If establishing the therapeutic relation-
ship proves particularly difficult, the two-weekly sessions
can be prolonged for four more weeks. After 16 weeks
(16–20 sessions), 4 sessions will be given once every two
weeks during weeks 17–25, and as a maintenance treat-
ment there will be 6 monthly sessions of CBASP during
weeks 26–52.
Treatment as usual
At the three sites, treatment as usual is based on the exist-
ing Dutch multidisciplinary guidelines for depression
[18]. This means that, besides optimal medical care, treat-
ment as usual can consists of evidence-based psychother-
apies, such as Cognitive Behavioral Therapy,
Interpersonal Psychotherapy, or Short Psychoanalytic
Supportive Psychotherapy [43]. Other interventions that
may be part of the treatment offered for chronically
depressed patients are supportive or structured activities
and treatments that focus on relaxation, assertiveness,
running, or other tasks. The treatment package received by
patients in the treatment-as-usual condition will be regis-
tered throughout the study.
Pharmacotherapy
In both conditions drug treatment will be given, consist-
ing of guideline' driven antidepressant medication [18].
The pharmacotherapy will be supported by 'clinical man-
agement' [44]: brief sessions in which patients will be
informed about the importance of adherence and the
effects and side effects of medication. The psychiatrist will
change the dose or medication when necessary. The use of
medication (name, dose given, and blood levels if availa-
ble) will be registered for all patients participating in the
study. Patients who refuse to use medication will not be
excluded, because CBASP has also been found to be effec-
tive as a monotherapy for chronically depressed patients
[13].
Economic evaluation
An economic evaluation will be performed from a societal
public health perspective. All direct and indirect costs will
be taken into account. Both direct costs within the health
care system (e.g., costs of visits to GP, specialist, and ther-
apist, hospital admissions, and medication use) and
direct costs outside the health care system (e.g., costs of
self medication, consultations with complementary med-
icine, and informal care) will be measured and valued. All
direct costs will be considered because it is difficult to dis-
cern which costs are associated with the depressive disor-
der and which not. The cost-price of the CBASP
intervention will be assessed using the bottom-up
method. Data on health care utilization and work absen-
teeism are collected by the Perceived Need for Care ques-
tionnaire (PNCQ) [45] and the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness
(TIC-P) [46], which patients will fill out four times during
the study, at baseline, after 16 weeks, after 32 weeks and
at the end of the study, after 52 weeks. Medicine utiliza-
tion will be registered at baseline and during the study
until the end. Costs of health care utilization will be cal-
culated using cost prices, if available. Otherwise tariffs will
be used. Indirect costs will be calculated using the friction
cost method.
Sample size
Based on the findings of the study of Keller and colleagues
[13] it is estimated that the addition of CBASP to the exist-
ing treatment will lead to 25% more response in the inter-
vention condition compared to the control condition. To
demonstrate this difference 60 patients in each condition
(beta 0.80 and alpha 0.05) are necessary [47]. Assuming a
drop-out percentage of 25%, this means that 160 partici-
pants need to be recruited.
Analysis
Analysis of covariance, controlling for baseline value will
be used to estimate the overall treatment effectiveness
(difference in IDS score) at follow-up. The primary analy-
sis will be by 'intention to treat' using double sided tests.
Further exploratory analyses will also assess the impact of
other explanatory factors and will model the time course
of effects using the 16-week and 32-week measurements
in a panel analysis. Sensitivity analyses will include esti-
mating 'on treatment' effects, CACE (complier average
causal effects), and imputation of any missing values.
More sophisticated techniques will be used, like GEE anal-
ysis, to measure the longitudinal effects.
The main aim of the economic analysis is to compare the
two groups in terms of mean costs and cost-effectiveness.
Analysis will be performed according to intention-to-treat
principle. The primary outcome measure of the study will
be included in the cost-effectiveness ratios. Cost-effective-
ness ratios and cost-utility ratios will be calculated using
bootstrapping techniques according to the bias corrected
percentile method. Bootstrapped cost-effect pairs will be
graphically represented on a cost-effectiveness plane. Sen-
sitivity analyses will be performed to study variations inBMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
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prices or resource uses that are uncertain and significantly
contribute to the total costs.
Ethical principles
The participation in the study is voluntary. Participants
are informed that they can cancel their participation at
any time without disclosing reasons for their cancellation
and without negative consequences for their future care.
Participants will sign an informed consent.
Vote of the ethics committee
The design and conduct of the study was approved by the
Medical Ethics Committee of the VU University Medical
Center, Amsterdam.
Discussion
This study protocol is presented here to offer researchers
the opportunity to consider the methodological quality of
this study with a critical view. Therapists can benefit by
considering the information regarding the practical appli-
cations of the proposed protocol on chronically depressed
patients in secondary care.
The number of studies examining the effects of psycho-
therapy on chronically depressed patients is very small,
while chronic depression affects a large group of patients
in secondary care and this subgroup is notable for poorer
subjective well being and impaired social and occupa-
tional functioning compared to non-chronically
depressed patients [10]. Research into the effectiveness of
CBASP can make an important contribution to the
improvement of care for chronically depressed patients.
According to the results of Keller et al. (2000), 73% of
these patients can be effectively treated if CBASP is com-
bined with antidepressant medication. CBASP can also be
an alternative for patients who are not motivated for or
refractory to pharmacological treatment. Furthermore,
CBASP could also be effective as a maintenance treatment
[13-17].
Strengths and limitations
Many methodological requirements for a high quality
trial are met. Allocation is concealed through randomiza-
tion by an external researcher. Recruitment of the patients
will be done after the standard intake procedure at each
site. As this study takes place within the mood disorder
departments of three organizations for mental health care
in the Netherlands the results can, to a large extent, be
generalized to the population of chronically depressed
patients seen in secondary care in the Netherlands.
A limitation of the present study is that the assessments
will be performed by research nursing staff who cannot be
kept blind to the treatment condition of the included
patients, as is always the case in trials studying the effects
of psychotherapy. Nor are the patients blind to treatment
condition. In this study, however, the main outcome
measures are self-report questionnaires, which means that
they will not be influenced by the research nursing staff.
Timeframe of the study
In October 2006 a pilot study, supervised by McCullough,
has started to enable the therapists to gain experience with
this innovative intervention. In May 2007 the randomized
treatment study has been started up. Month 1–12: Screen-
ing and inclusion of chronically depressed patients at the
three locations. Start of the data collection for the treat-
ment study. Supervision of the treatments. Start of data
entry and purging of databases. Month 13–24: Comple-
tion of data collection. Completion of purging and analy-
sis of the data. Publication on these short-term findings.
Month 24–36: Completion of data collection of the fol-
low-up. Publication on the effectiveness of CBASP and the
follow-up effects. Dissemination of the results (e.g. pres-
entation of study results at national and international
conferences). Working on the implementation of CBASP
in the Netherlands.
Description of risks
There are no specific risks related to this study.
shows the procedures in a flow chart Figure 1
shows the procedures in a flow chart.
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End-Interview    
(T=4, 52 wks) 
CBASP  
(n=80) 
  
Referred patients with 
chronic  depression BMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
Page 7 of 8
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
PvO, DvS and AB developed the design of the randomized
clinical trial and participated in writing the article. JM, RS,
JD, MB, KM, BP and JS advised on the content of the arti-
cle and supervise the project. JW is the principal investiga-
tor and writer of this manuscript. All authors have read
and approved the final version of the manuscript.
Acknowledgements
This study is financed by ZonMw – the Netherlands Organization for 
Health research and Development, grant-number 100-003-022 and by the 
foundation of Support (Stichting tot Steun).
References
1. Levav I, Rutz W: The WHO World Health Report 2001 new
understanding--new hope.  Isr J Psychiatry Relat Sci 2002, 39:50-56.
2. Simon GE, Chisholm D, Treglia M, Bushnell D: Course of depres-
sion, health services costs, and work productivity in an inter-
national primary care study.  Gen Hosp Psychiatry 2002,
24:328-335.
3. Spijker J, de GR, Bijl RV, Beekman AT, Ormel J, Nolen WA: Dura-
tion of major depressive episodes in the general population:
results from The Netherlands Mental Health Survey and
Incidence Study (NEMESIS).  Br J Psychiatry 2002, 181:208-213.
4. Mueller TI, Keller MB, Leon AC, Solomon DA, Shea MT, Coryell W,
Endicott J: Recovery after 5 years of unremitting major
depressive disorder.  Arch Gen Psychiatry 1996, 53:794-799.
5. Klein DN, Schwartz JE, Rose S, Leader JB: Five-year course and
outcome of dysthymic disorder: A prospective, naturalistic
follow-up study.  Am J Psychiatry 2000, 157:931-939.
6. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ,
Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM,
Keller MB: The treatment of chronic depression, part 3: psy-
chosocial functioning before and after treatment with ser-
traline or imipramine.  J Clin Psychiatry 1998, 59:608-619.
7. Rush AJ, Laux G, Giles DE, Jarrett RB, Weissenburger J, Feldman-Kof-
fler F, Stone L: Clinical characteristics of outpatients with
chronic major depression.  J Affect Disord 1995, 34:25-32.
8. Keller MB, Hanks DL, Klein DN: Summary of the DSM-IV mood
disorders field trial and issue overview.  Psychiatr Clin North Am
1996, 19:1-28.
9. McCullough JP: Treatment for Chronic Depression. Cognitive Behavioral
Analysis System of Psychotherapy. New York: The Guilford Press; 2000. 
10. Arnow BA, Constantino MJ: Effectiveness of psychotherapy and
combination treatment for chronic depression.  J Clin Psychol
2003, 59:893-905.
11. Wachtel PL: Psychodynamics, behavior therapy, and the
implacable experimenter: an inquiry into the consistency of
personality.  J Abnorm Psychol 1973, 82:324-334.
12. Arnow BA: Cognitive Behavioral Analysis System of Psycho-
therapy for Chronic Depression.  Cognitive and Behavioal practice
2005, 12:6-16.
13. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelen-
berg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi
MH, Zajecka J: A comparison of nefazodone, the cognitive
behavioral-analysis system of psychotherapy, and their com-
bination for the treatment of chronic depression.  N Engl J Med
2000, 342:1462-1470.
14. Kocsis JH, Rush AJ, Markowitz JC, Borian FE, Dunner DL, Koran LM,
Klein DN, Trivedi MH, Arnow B, Keitner G, Kornstein SG, Keller MB:
Continuation treatment of chronic depression: a compari-
son of nefazodone, cognitive behavioral analysis system of
psychotherapy, and their combination.  Psychopharmacol Bull
2003, 37:73-87.
15. Klein DN, Santiago NJ, Vivian D, Blalock JA, Kocsis JH, Markowitz JC,
Cullough Jr JP, Rush AJ, Trivedi MH, Arnow BA, Dunner DL, Manber
R, Rothbaum B, Thase ME, Keitner GI, Miller IW, Keller MB: Cogni-
tive-behavioral analysis system of psychotherapy as a main-
tenance treatment for chronic depression.  J Consult Clin Psychol
2004, 72:681-688.
16. Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN,
Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RM, Keitner GI,
Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnow B, Roth-
baum B, Munsaka M, Banks P, Borian FE, Keller MB: Randomized,
placebo-controlled trial of nefazodone maintenance treat-
ment in preventing recurrence in chronic depression.  Biol Psy-
chiatry 2003, 54:806-817.
17. Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE,
Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markow-
itz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Kel-
ler MB: Chronic depression: medication (nefazodone) or
psychotherapy (CBASP) is effective when the other is not.
Arch Gen Psychiatry 2005, 62:513-520.
18. Landelijke Stuurgroep Multidisciplinaire Richtlijnon-
twikkeling in de GGZ [2005]. Richtlijn voor de diagnostiek
en behandeling van volwassen cliënten met een depressie
2005.    2005 [http://www.ggzrichtlijnen.nl].
19. Pinninti NR, Madison H, Musser E, Rissmiller D: MINI International
Neuropsychiatric Schedule: clinical utility and patient
acceptance.  Eur Psychiatry 2003, 18:361-364.
20. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller
E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neu-
ropsychiatric Interview (M.I.N.I.): the development and vali-
dation of a structured diagnostic psychiatric interview for
DSM-IV and ICD-10.  J Clin Psychiatry 1998, 59 Suppl 20:22-33.
21. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inven-
tory of Depressive Symptomatology (IDS): psychometric
properties.  Psychol Med 1996, 26:477-486.
22. Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keit-
ner GI, Kornstein SG, Arnow B, Klein DN, Manber R, Dunner DL,
Gelenberg AJ, Kocsis JH, Nemeroff CB, Fawcett J, Thase ME, Russell
JM, Jody DN, Borian FE, Keller MB: Self-reported depressive
symptom measures: sensitivity to detecting change in a ran-
domized, controlled trial of chronically depressed, nonpsy-
chotic outpatients.  Neuropsychopharmacology 2005, 30:405-416.
23. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN,
Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis
JH, Keller MB: The 16-Item Quick Inventory of Depressive
Symptomatology (QIDS), clinician rating (QIDS-C), and self-
report (QIDS-SR): a psychometric evaluation in patients
with chronic major depression.  Biol Psychiatry 2003, 54:573-583.
24. Spijker J, Nolen WA: Predictive factors for chronicity of
depression. A literature review.  Tijdschrift voor Psychiatrie 1998,
40:696-708.
25. Organization WH: International Classification of Functioning,
Disability and Health.  Geneva: World Health Organization; 2001. 
26. De Jong Gierveld J, Kamphuis FH: The development of a Rasch
type Loneliness Scale.  Applied Psychological Measurement 1989,
9:289-299.
27. Sheehan TJ, DeChello LM, Garcia R, Fifield J, Rothfield N, Reisine S:
Measuring disability: application of the Rasch model to activ-
ities of daily living (ADL/IADL).  J Outcome Meas 2001,
5:839-863.
28. Pearlin LI, Schooler C: The structure of coping.  J Health Soc Behav
1978, 19:2-21.
29. Dierendonck D: The construct validity of Ryff's scales of Psy-
chological Well-Being and its extension with spiritual well-
being.  Personality and Individual Differences 2004, 36:629-643.
30. Von Korff M: Epidemiologic and Survey Methods: Chronic
Pain Assessment.  New York: guilford Press; 2001:603-618. 
31. Denollet J, Smolderen KG, van den Broek KC, Pedersen SS: The 10-
item Remembered Relationship with Parents (RRP10) scale:
two-factor model and association with adult depressive
symptoms.  J Affect Disord 2007, 100:179-189.
32. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE
Jr., Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS,
Zajecka J: Development and validation of a screening instru-
ment for bipolar spectrum disorder: the Mood Disorder
Questionnaire.  Am J Psychiatry 2000, 157:1873-1875.
33. Lyketsos CG Nestadt,G.,Cwi,J.,Heithoff,K.,Eaton,W.W.: The Life
Chart Interview: a standardized method to describe thePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Psychiatry 2008, 8:18 http://www.biomedcentral.com/1471-244X/8/18
Page 8 of 8
(page number not for citation purposes)
course of psychpathology.  International Journal of Methods of Psy-
chiatric Research 1994, 4:143-155.
34. Beck AT, Steer RA: Beck Anxiety Inventory manual, 2nd edition San
Antonio TX, Psychological Corporation; 1993. 
35. Schmidt A, Barry KL, Fleming MF: Detection of problem drinkers:
the Alcohol Use Disorders Identification Test (AUDIT).
South Med J 1995, 88:52-59.
36. Brugha T, Bebbington P, Tennant C, Hurry J: The List of Threaten-
ing Experiences: a subset of 12 life event categories with con-
siderable long-term contextual threat.  Psychol Med 1985,
15:189-194.
37. De Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J: Risk factors
for 12-month comorbidity of mood, anxiety, and substance
use disorders: findings from the Netherlands Mental Health
Survey and Incidence Study.  Am J Psychiatry 2002, 159:620-629.
38. Hoekstra HA, Ormel J, De Fruyt F: De NEO-PI-R/NEO-FFI; Big Five per-
soonlijkheidsvragenlijsten. Handleiding [Manual of the Dutch version of the
NEO-PI-R/NEO-FFI] Lisse, Swets en Zeitlinger; 1996. 
39. Horvath AO, Greenberg LS: Development and Validation of the
Working Alliance Inventory.  Journal of Counseling Psychology 1989,
36:223-233.
40. McCullough JP: Therapist manual for Cognitive Behavioral Analysis System
of Psychotherapy. Richmond: Virginia Commonwealth University;
1995. 
41. McCullough JP: Skills training manual for diagnosing and treating chronic
depression New York: The Guilford Press; 2001. 
42. McCullough JP: Patient's Manual for CBASP. New York: The Guilford
Press; 2002. 
43. F. J, Hendricksen M, van AG, Kool S, Peen V, Van R, van den EE,
Dekker J: Psychotherapy alone and combined with pharmaco-
therapy in the treatment of depression.  Br J Psychiatry 2004,
185:37-45.
44. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH: Clinical manage-
ment--imipramine/placebo administration manual. NIMH
Treatment of Depression Collaborative Research Program.
Psychopharmacol Bull 1987, 23:309-324.
45. Meadows G, Burgess P, Bobevski I, Fossey E, Harvey C, Liaw ST: Per-
ceived need for mental health care: influences of diagnosis,
demography and disability.  Psychol Med 2002, 32:299-309.
46. Hakkaart-Van Roijen L: Trimbos/iMTA questionnaire for Costs
associated with Psychiatric Illness (Tic-P).  Institute for Medical
Technology Assessment; 2002. 
47. Cohen J: Statistical power analysis for the behavioral sciences Hillsdale:
Lawrence Erlbaum Associates; 1998. 
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-244X/8/18/pre
pub